Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Ceritinib versus chemotherapie bij gevorderd ALK-positief NSCLC: ASCEND-4
mrt 2017 | Longoncologie